Seegene

Seegene ROIC

The Return on Invested Capital (ROIC) of Seegene (096530.KQ) as of Nov 7, 2026 is 4.75 %. In the previous year, Return on Invested Capital (ROIC) was -2.08 % — a change of -328.89% (higher).

ROIC

4.75 %

YoY

-328.89%

Last updated:

Return on Invested Capital (ROIC) of Seegene is 2025 4.75 % . Return on Invested Capital (ROIC) of Seegene was 2024 -2.08 % . It decreases by -328.89% higher compared to the previous year.

The Seegene ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
7.76 KRW
Jan 1, 2019
15.91 KRW
Jan 1, 2020
67.12 KRW
Jan 1, 2021
43.25 KRW
Jan 1, 2022
13.94 KRW
Jan 1, 2023
0.07 KRW
Jan 1, 2024
-2.08 KRW
Jan 1, 2025
4.75 KRW
The Seegene ROIC history
YEARROICYoY
4.75 %-328.89%
-2.08 %-3,294.20%
0.07 %-99.53%
13.94 %-67.78%
43.25 %-35.55%
67.12 %+321.85%
15.91 %+105.06%
7.76 %+465.07%
1.37 %-63.02%
3.71 %-0.83%
3.74 %-48.62%
7.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

Return on Invested Capital (ROIC) of Seegene is 4.75 % in 2025.

Return on Invested Capital (ROIC) of Seegene changed from -2.08 % to 4.75 %, representing a -328.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Seegene since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Seegene with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Seegene

All Key Metrics — Seegene